Table 2.
Glucose control, HbA1c, insulin delivered during baseline and study phase
| MDI, Baseline | HCL, 1–3 months |
p | HCL, 4–6 months |
p | HCL, 7–9 months |
p | HCL, 10–12 months |
p | |
|---|---|---|---|---|---|---|---|---|---|
| HbA1c, % | 8.2 ± 1.4 | 6.7 ± 0.8 | 0.02 | 6.9 ± 0.7 | 0.03 | 6.8 ± 0.5a | 0.03 | 7.1 ± 0.6a | 0.02 |
| HbA1c, mmol/mol | 66 ± 15.3 | 50 ± 8.7 | 52 ± 7.7 | 51 ± 5.5 | 54 ± 6.6 | ||||
| SG (12 am–12 am), mg/dl | 193 ± 41 | 142 ± 12 | 0.01 | 146 ± 20 | 0.01 | 141 ± 14 | 0.01 | 149 ± 18 | 0.01 |
| SG (10 pm–06 am), mg/dl | 183 ± 35 | 133 ± 17 | 0.02 | 138 ± 16 | 0.02 | 132 ± 15 | 0.01 | 136 ± 14 | 0.02 |
| SG (06 am–10 pm), mg/dl | 202 ± 42 | 150 ± 10 | 0.01 | 145 ± 17 | 0.01 | 149 ± 12 | 0.02 | 155 ± 21 | 0.02 |
| Weight, kg | 38.2 ± 12.5 | 39.4 ± 8.9 | 0.63 | 40.2 ± 8.1 | 0.61 | 41.7 ± 7.2 | 0.58 | 42.8 ± 8.2 | 0.50 |
| TDD, U/(kg/d) | 0.8 ± 0.3 | 0.9 ± 0.2 | 0.02 | 0.9 ± 0.3 | 0.02 | 0.9 ± 0.3 | 0.02 | 0.9 ± 0.5 | 0.02 |
| Basal insulin, (12 am–12 am), % | 36.5 ± 7.2 | 42.2 ± 6.7 | 0.03 | 43.3 ± 8.8 | 0.04 | 42.5 ± 10.2 | 0.04 | 43.8 ± 9.8 | 0.04 |
Results presented as mean ± SD; p-value at 3 months represents change from baseline to 3 months; p-value at 6 months represents change from baseline to 6 months; p-value at 9 months represents change from baseline to 9 months; p-value at 12 months represents change from baseline to 12 months
SG sensor glucose; TDD total daily dose; U units; d, day
aDue to Covid-19 Pandemic and disruption in clinical services, HbA1c was obtained in 26/30 participants at 9 months and 27/30 participants at 12 months